

## Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients

Massimo Nabissi<sup>1</sup>, Maria Beatrice Morelli<sup>2</sup>, Antonietta Arcella<sup>3</sup>, Claudio Cardinali<sup>2</sup>, Matteo Santoni<sup>4</sup>, Giovanni Bernardini<sup>2,3</sup>, Angela Santoni<sup>2,3</sup>, Giorgio Santoni<sup>1</sup>, Consuelo Amantini<sup>5</sup>

<sup>1</sup>School of Pharmacy, Experimental Medicine Section, University of Camerino, Camerino (MC), Italy

<sup>2</sup>Department of Molecular Medicine, Sapienza University, Rome (RM), Italy

<sup>3</sup>I.N.M. Neuromed, Pozzilli, Isernia (IS), Italy

<sup>4</sup>Department of Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona (AN), Italy

<sup>5</sup>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino (MC), Italy

**Correspondence to:** Massimo Nabissi, **email:** massimo.nabissi@unicam.it  
Consuelo Amantini, **email:** consuelo.amantini@unicam.it

**Keywords:** TRPV1, glioblastoma, 5'UTR, survival rate, prognosis

**Received:** August 02, 2016

**Accepted:** October 14, 2016

**Published:** November 05, 2016

### ABSTRACT

**The Transient Receptor Potential Vanilloid type-1 (TRPV1) channel is a non-selective cation channel belonging to the Transient Receptor Potential family; variation of its expression has been correlated to glioma progression. In human, TRPV1 transcripts display a remarkable homogeneity differing only for the 5'-untranslated region (5'UTR) sequence that generates four variants encoding the same protein. Herein, we investigated the role of the 5'UTR sequences in TRPV1 transcripts stability, regulation of translation, expression in glioma cells and tissues. In addition, the expression of 5'UTR TRPV1 variants as prognostic factor in the survival of glioblastoma patients was evaluated. The expression level for each 5'UTR and their stability was evaluated by RT-PCR analysis. The effect of rapamycin and interferon-gamma in 5'UTR-regulating TRPV1 translation was determined by western blot analysis in glioma cell lines. We demonstrated that the 5'UTR influences the stability and translation efficacy of TRPV1 transcripts, and that TRPV1 variant three (TRPV1<sub>v3</sub>) was the most stable and the only variant expressed in GBM samples and in glioma stem-like cells. Furthermore, we found that TRPV1<sub>v3</sub> expression levels correlate with patient's survival, suggesting that it may represent a potential prognostic marker for patients with glioma.**

### INTRODUCTION

The Transient Receptor Potential Vanilloid type-1 (TRPV1) channel is a non-selective cation channel structurally related to members of the Transient Receptor Potential (TRP) family. The gene encoding the human TRPV1 (ENSG00000196689) is located on Chromosome 17: 3,565,444-3,609,411 reverse strand and covers a region of 44 Kb. The canonical form of TRPV1 comprises 839 aa (MW ≈ 96 kDa) and is composed of six trans-membrane spanning domains and a pore loop domain between

trans-membrane domains 5 and 6 [1]. The N-terminal and C-terminal tails are on the cytoplasmic side. Three N-terminal ankyrin (ANK) repeats spanning amino acids 101-304 are present in N-terminal tail [2]. In TRP channel families, alternative splicing enables the same gene to generate multiple mature RNA types for translation, resulting in multiple channel proteins [3]. At present three different TRPV1 splice variants have been identified: the Vanilloid Receptor 5' splice variant (VR.5'sc), the TRPV1beta (TRPV1β) and the TRPV1 variant (TRPV1var) [4]. The VR.5'sc variant, identified in rat, originates

from an alternative initiation of translation resulting in a truncated N-terminal intracellular domain and on the skipping of an exon, resulting in the loss of 60 aa encoding for a N-terminal intra-terminal region including the third ankyrin repeat domain; the TRPV1 $\beta$ , described in a human clone that lacked exon 7 (30 nucleotide loss) encoding a portion of the third ankyrin repeat domain [5]; TRPV1 $\var$ var isolated from rat kidney papilla resulting from the failure to splice out intron 5 [6]. In addition, although TRPV1 transcripts display a remarkable homogeneity in the open reading frame and in the 3'-untranslated regions (3'UTR), different 5'-untranslated region (5'UTR) sequence due to alternative 1st exon, generates four variants (TRPV1 $_{v1}$ , TRPV1 $_{v2}$ , TRPV1 $_{v3}$ , TRPV1 $_{v4}$ ) encoding the same protein, with TRPV1 $_{v2}$  sharing 100% homology with TRPV1 wild type (TRPV1 $_{v0}$ ). In-frame stop codon immediately upstream of the translation start site ensures that the 5' variability occurs at the mRNA level, with only the 5'UTR affected by the alternative 1st exon [2]. The 5'UTR is a major site of regulation of translation, since it contains both *cis*- and *trans*-acting elements that contribute to qualitative and quantitative regulation of this process [7]. Elements in 5'UTR, such as upstream open reading frames (uORFs), internal ribosome entry sites (IRES) [8, 9], RNA G-quadruplexes [10], terminal oligopyrimidine tract (TOP) [11], gamma interferon activated inhibitor of ceruloplasmin mRNA translation (GAIT) [12], have been demonstrated to affect translation. In addition, the length and the GC content in the 5'UTR can influence the translation of the main ORFs [13, 14]. So, 5'UTR elements can influence regulation of gene expression and are associated with the development of human diseases by controlling mRNA stability and translational efficiency, as in cancer [15]. In human cancer, TRPV1 has been found to activate a cell death program in prostate [16], colon [17], pancreas [18], breast [19] and bladder cancer [20, 21]. Moreover, TRPV1 is also involved in glioma progression and changes of its expression contribute to malignancy. We have previously reported that TRPV1 is expressed in glioma tissues but not in epileptic brain tissues, with an inverse correlation between TRPV1 expression levels and pathological glioma grade [22]. Moreover, neural precursor cell stimulation of TRPV1 has been found to trigger high-grade glioma cell death, activating the ATF3 transcription factor controlling ER stress pathway [23, 24]. Finally, it has been recently reported at mRNA level, that TRPV1 was over-expressed in glioblastoma (GBM) patients with higher overall survival (OS, more than 12 months) as respect to those showing lower OS (less than 12 months) [25]. Since 5'UTRs of the human TRPV1 transcripts could play a role in TRPV1 stability and translational efficiency, we investigated the involvement of 5'UTR sequences in TRPV1 stability, regulation of TRPV1 protein synthesis and expression in GBM cell lines. Moreover, the expression of 5'UTR TRPV1 variants in GBM, glioma stem-like cells (GSCs) and the 5'UTR

TRPV1 variants role as prognostic factor in the survival of GBM patients have been evaluated.

## RESULTS

### The 5'UTR regions influence the RNA secondary structure of TRPV1 transcripts

The 5'UTR of TRPV1 mRNA transcripts were selected from the mRNA sequences available in UNIGENE database. Five 5'UTR variants, named TRPV1 $_{v0-4}$ , were present and they differed for the length of 5'UTR (Table 1), except for TRPV1 $_{v0}$  and TRPV1 $_{v2}$  that showed 100% nucleotide sequence homology. ORF and 3'UTR regions, showed 100% nucleotide sequence homology in all the TRPV1 5'UTR variants. Therefore, for the structure analysis of TRPV1 5'UTR we selected TRPV1 $_{v0}$ ,  $_{v1}$ ,  $_{v3}$ ,  $_{v4}$  variants. First, the evaluation of the 5'UTR length and GC content evidenced that the TRPV1 $_{v3}$  is the longest (527 nt), followed by TRPV1 $_{v1}$  (275 nt), TRPV1 $_{v4}$  (201 nt) and TRPV1 $_{v0}$  (158 nt), while GC content was higher in TRPV1 $_{v0}$  (65.8%), followed by TRPV1 $_{v3}$  (62.2%), TRPV1 $_{v1}$  (58.2%) and TRPV1 $_{v4}$  (54.7%) (Supplementary Table 1). Since the 5'UTR sequence appeared to influence the overall topology of the complete mRNA and the GC content was correlated with the thermodynamic stability of RNA secondary structure, we predicted the free energy of the secondary structure both of 5'UTRs and of the full length TRPV1 5'UTR variant sequences, using the mFold software. As shown (Figure 1) the TRPV1 $_{v3}$  transcript has the lower free energy, followed by TRPV1 $_{v4}$ , TRPV1 $_{v1}$  and TRPV1 $_{v0}$ , while considering the 5'UTR, TRPV1 $_{v3}$  lower free energy was followed by that of TRPV1 $_{v1}$ , TRPV1 $_{v4}$  and TRPV1 $_{v0}$ . Overall, for any TRPV1 variant, we evaluated the RNA sequence length, the GC content and the estimated free energy. Since the mRNA with the most negative value of free energy is considered the most structured and the most stable, these results suggest that TRPV1 $_{v3}$  should be the most stable TRPV1 variant transcript.

### The 5'UTR modulates the half-life of TRPV1 variant transcripts

In order to investigate the role of the 5'UTR in regulating mRNA stability, we measured the half-life of the TRPV1 5'UTR variant mRNAs, in U87 and U251 glioma cell lines. The two cell lines were treated with actinomycin D (Act D, 10  $\mu$ M) to block transcription, and the exponential decay was followed up to 10 h post-treatment. As shown (Figure 2A), the effect of Act D on RNA transcription, evaluated by agarose gel electrophoresis, clearly demonstrated a reduction of total RNA quantity, just after 6 h of treatment. The results indicate that the TRPV1 variants are expressed at different levels in both cell lines (Figure 2B). Higher TRPV1 $_{v3}$


**Table 1: Comparative sequence analysis of the TRPV1 5'UTR variants**

TRPV1 <sub>v3</sub>  ref NM_080706.3	CTGCCGCTCACCTATTCCAGGGACA-CAGTCTGCTTGGCTCTTCTGGAC	49
TRPV1 <sub>v4</sub>  ref NM_080705.3	-----GCA-GAGTGTGC--AG---TATAGAT	20
TRPV1 <sub>v1</sub>  ref NM_080704.3	-----GGCTCAGGCAGGCCTGG---CCCAGAG	24
TRPV1 <sub>v0</sub>  ref NM_018727.5	-----GCCCGGG-----A---CCC---	11
gi 117306163 ref NM_080706.3	TGAGCCATCCTCATCACCGAGATCCTCCCTGAATTCAGCCCACGACAGCC	99
gi 117306162 ref NM_080705.3	TCAGCGTTTGTGCG--ACTGA-----CTGAATG-----ATAGCA-CA	53
gi 117306161 ref NM_080704.3	TCA-CGCTGGCAACCAC-GAG-----TTTGGGAA-----GCAGTCGTA	60
gi 117306160 ref NM_018727.5	-CA-CGGAGGCG-----GGGAG-----AC-----	28
gi 117306163 ref NM_080706.3	ACCCCGGCCGTTTTCCTTGTCTGTGTGGGGAGGGAGGCAGCGCGGTGGT	149
gi 117306162 ref NM_080705.3	ATCCCGGCTGCTTCC--TGTT-----	72
gi 117306161 ref NM_080704.3	TTCTCTCTCTCTCTCTCTC-----	81
gi 117306160 ref NM_018727.5	---CACTCT-----	34
gi 117306163 ref NM_080706.3	TATCAACCTCACCTGCAGAGGAGGCACCTGAGGCCAGAGACGAGGAGG	199
gi 117306162 ref NM_080705.3	-----G	73
gi 117306161 ref NM_080704.3	-----TCTC	85
gi 117306160 ref NM_018727.5	-----TCTC	38
gi 117306163 ref NM_080706.3	GATGGGTCTAACCCAGAACCACAGATGGC-TCTGAGCCGGGGCCTGTCC	248
gi 117306162 ref NM_080705.3	GCTGGGTTT-----GGT-T-----	86
gi 117306161 ref NM_080704.3	TCTCAGTATCCATGA-----CAGTGTGAT-----	109
gi 117306160 ref NM_018727.5	CCACACGAGCC-----CAG-----	52
gi 117306163 ref NM_080706.3	ACCCTCCCAGGCCGACGTCAGTGGCCGAGGA-----CTGCCTGGGCCC	292
gi 117306162 ref NM_080705.3	-----GGA-----CTG--GGACCC	98
gi 117306161 ref NM_080704.3	-----GGAGAGTCTCTGCC-GTGCC-	128
gi 117306160 ref NM_018727.5	-----CTCTCCC-----	59
gi 117306163 ref NM_080706.3	TGCTAGGCCTGCTCACCTCTGAGGCCTCTGGGGTGAGAGGTTTCAGTCCTG	342
gi 117306162 ref NM_080705.3	-----GTCAGAGG-----	106
gi 117306161 ref NM_080704.3	-----ATCTGGGATGC-----	139
gi 117306160 ref NM_018727.5	-----TTCGAGTAGC-----	69
gi 117306163 ref NM_080706.3	GAAACACTTCAGTTCTAGGGGGCTGGGGGC---AGCAGCAAGTTGGAGT	388
gi 117306162 ref NM_080705.3	AAAA-----GGC---AAC-----	116
gi 117306161 ref NM_080704.3	AAACCGTCCCTGTGTTCCCCACGTCCAGGCCGTAGAT-----	176
gi 117306160 ref NM_018727.5	AA-----CCGCCTTCAAGC-----	83
gi 117306163 ref NM_080706.3	TTTGGGGTACCCTGCTTACAGGGC---CCTTGGAAGGAGGGCAGGTG	434
gi 117306162 ref NM_080705.3	-----GC---CGCTGACAAAGAACATTGCCG	139

*(Continued)*

gi 117306161 ref NM_080704.3	-----GCTCCCCGCCGGTCAGTCACTTAGTCG	203
gi 117306160 ref NM_018727.5	-----TCAC-----	87
gi 117306163 ref NM_080706.3	GGGTCTAAGGACAAGCAGTCCTTAC---TTTGGGAGT---CAACCCCGGC	478
gi 117306162 ref NM_080705.3	A----AAGG-----TTCA-----TGGGAG-----GCTCCGGC	162
gi 117306161 ref NM_080704.3	T----CAGATCG-----CCCGT--CCTGGTATCACAGTGCTTCTGT	238
gi 117306160 ref NM_018727.5	-----AAGCA-----CCCGTGGGCCTGGGGT---GTGCCTGCGT	118
gi 117306163 ref NM_080706.3	GTGGTGGCTGCTGCAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA	525
gi 117306162 ref NM_080705.3	-----TAACAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA	199
gi 117306161 ref NM_080704.3	-----TCAG---GTTGCACACTGGGCCACAGAGGATCCAGCAA	273
gi 117306160 ref NM_018727.5	-----CTAGCTGGTTGCACACTGGGCCACAGAGGATCCAGCAA	156
gi 117306163 ref NM_080706.3	GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC	575
gi 117306162 ref NM_080705.3	GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC	249
gi 117306161 ref NM_080704.3	GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC	323
gi 117306160 ref NM_018727.5	GGATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTC	206

Gene bank accession number (gi and NM\_) are indicated.




**Figure 1: Secondary structure and free-energy value of the TRPV1 5'UTR variants and full-length sequences.** Folding of 5'UTR TRPV1 variants and of the corresponding full length TRPV1 RNA transcripts predicted by the mFold program. Predicted secondary structures of lowest free energy were represented in kcal/mol.

level, followed by TRPV1<sub>v4</sub>, TRPV1<sub>v0</sub> and TRPV<sub>v1</sub> were observed. Time course analysis in Act D-treated samples evidences that the TRPV1<sub>v3</sub> is the most stable with a Ct decay (Ct time 0 – Ct time 8,  $\Delta$  Ctd) of 2, followed by TRPV1<sub>v4</sub> ( $\Delta$ Ctd = 7.4), TRPV1<sub>v0</sub> ( $\Delta$ Ctd = 8.3) and finally TRPV1<sub>v1</sub> with a total decay, after 8 h of treatment. Overall, these results indicate that TRPV1 variants stability is correlated to their free energy value, confirming that TRPV1<sub>v3</sub> is the most stable transcript.

### TOP motif in 5'UTR regulates TRPV1 translation

Since motifs present in 5'UTR are known to regulate protein translation, we analyzed TRPV1 5'UTR sequences by using RegRNA, a regulatory RNA motifs and element finder. As shown (Table 2), software analysis identified different regulatory elements in all of the TRPV1 5'UTR sequences. uORF motif was found in each TRPV1<sub>v1, v3, v4</sub> and an IRES was found in TRPV1<sub>v4</sub> only. Regarding uORF,

it is considered that all type of uORF can reduce protein expression, and specifically, three uORF properties are associated with greater inhibition: strong uAUG context, increased distance from the cap (cap-uORF distance > 50 nt negative influence translation) and multiple uORF in the 5'UTR. Sequence analysis of TRPV1 5'UTRs indicated similar properties in all TRPV1 5'UTR sequences: one single uORF is present in TRPV1<sub>v1,3,4</sub>, cap-uORF > 50 and strong uAUG context. These analyses suggest that uORF in TRPV1 5'UTR should not influence different translation efficacy in TRPV1 5'UTR variants. TOP that makes mRNA translation sensitive to rapamycin (Rap) was found in all TRPV1 5'UTRs sequences. To address the importance of the 5'TOP motif in serving as inhibitory target of Rap in suppressing the translation of the TRPV1 5'UTR variants, we treated U87 and U251 cell lines with 10  $\mu$ M Rap for 24 h. TRPV1 protein levels, evaluated by western blot analysis, in Rap-treated cells, evidenced a strong reduction of TRPV1 translation compared with control cells (Figure 3A), suggesting



**Figure 2: Time-dependent TRPV1 5'UTR variant transcripts stability in U87 and U251 cell lines.** **A.** Representative image of total RNA from Act D-treated U87 and U251 glioma cell lines analyzed by agarose gel electrophoresis, up to 10 h post-treatment, **B.** Ct value at different times (2, 4, 6 and 8 h) post-Act D treatment. Time 10 h was omitted since no TRPV1 transcripts expression was detected. Data were obtained by RT-PCR analysis and represented one out of three separate experiments.

**Table 2: Motifs in TRPV1 5'UTR**

**TRPV1<sub>v0</sub>**

No.	RegRNA ID	Location	Length (nt)	Sequence
1	TOP	53-63	11	CTCTCCCTTCG
2	GAIT	74-98 107-134	25 28	CGGTTGCTACTGAAGGGAGAGCTG GTGTGCCTGCGTCAGCTGGTTGCACAC

**TRPV1<sub>v1</sub>**

No.	RegRNA ID	Location	Length (nt)	Sequence
1	TOP	117~121 147~151 178~184 232~237	5 5 7 6	CTCTG CCCTG CTCCCCG CTTCTG
2	uORF	97~174	78	ATGACAGTGTGATGGAGAGTCTCTGCCGTGC CATCTGGGATGCAAACCGTCCCTGTGT TCCCCACGTCCAGGCCGTAG

**TRPV1<sub>v3</sub>**

No.	RegRNA ID	Location	Length (nt)	Sequence
1	TOP	39~46 73~80 101-105 114-118 161-165 228-232 290-294 308-313 317-322 398-402 413-418 459-463 472-476	8 8 5 5 5 5 5 6 6 5 6 5 5 5	CTCTTCTG CCTCCCTG CCCCG CCTTG CCCTG CTCTG CCCTG CCTCTG CCTCTG CCCTG CCCTG CTTTG CCCCG
2	uORF	201-314	114	ATGGGTCTAACCCAGAACCACAGATGGCTC TGAGCCGGGGCCTGTCCACCCTCCCAGGC CGACGTCAGTGGCCGAGGACTGCCTGGGC CCTGCTAGGCCTGCTCACCTCTGA
3	GAIT	27-51 110-134 110-136 110-137 392-416 438-465 109-133	25 25 27 28 25 28 25	CAGTCTGCTGGCTCTTCTGGACTG TTTTCTTGTTCTGTGTGGGGAGGG TTTTCTTGTTCTGTGTGGGGAGGGAG TTTTCTTGTTCTGTGTGGGGAGGGAGG GGGGTACCCTGCTTCACAGGGCCCT TCTAAGGACAAGCAGTCCCTACTTTGGG CGGCCGGGTGGCTGTCTGGGGCTG

**TRPV1<sub>v4</sub>**

No.	RegRNA ID	Location	Length (nt)	Sequence
1	TOP	64-70 156-160	7 5	CTTCCTG CTCCG
2	uORF	43-165	123	ATGATAGCACAATCCCGGCTGCTTCCTGTT GGCTGGGTTTGGTTGGACTGGGACCCGTC GAGGAAAAGGCAACGCCGCTGACAAAGAAC ATTGCCGAAAGGTTTCATGGGAGGCTCCGGCTAA
4	GAIT	19-44	26	ATTCAGCGTTTGTCTGACTGACTGAAT

RegRNA ID are represented, Location (as nucleotide position in 5'UTR mRNA region, Length in bases (b) and the relative nucleotide sequence. Terminal Oligopyrimidine Tract (TOP), Gamma Interferon activated inhibitor of Ceruloplasmin mRNA translation (GAIT), Upstream Open Reading Frame (uORF), Internal Ribosome Entry Site (IRES).

that Rap, through 5' TOP motif, was able to suppress TRPV1 translation. In addition, by RegRNA analysis, the presence of an interferon-gamma (IFN- $\gamma$ ) activated inhibitor of translation (GAIT) element was determined in 5' UTR of TRPV1<sub>v0, v3, v4</sub>. Since mRNAs with GAIT element are supposed to be negatively regulated by IFN- $\gamma$ , we treated U87 and U251 cell lines with IFN- $\gamma$  (100  $\mu$ M) for 24 h. After treatments, we analyzed the levels of TRPV1 transcript by western blot analysis, and the results evidenced a reduced expression of TRPV1 proteins in both glioma cell lines, mainly in U87 cells (Figure 3B), suggesting that IFN- $\gamma$  was able to negatively regulate GAIT-TRPV1 variants translation, with levels of TRPV1 protein likely sustained by the TRPV<sub>v1</sub> expression that does not contain a GAIT element in its 5'UTR region.

### TRPV1 5'UTR variants expression in glioma tissues and GSCs


To evaluate which TRPV1 5'UTR variant was expressed in glioma samples, we analyzed the expression of TRPV1 5'UTR variants in different glioma biopsies, from grade I to IV (n = 84) obtained from mixed patients (Supplementary Table 2), in normal brain (NB; n= 3) and in normal human astrocytes (NHA; n = 3) samples, by RT/PCR analysis. As shown NB, NHA and glioma grade I samples expressed at different levels all the 5'UTR TRPV1 variant transcripts, while some samples resulted express the TRPV1 variants: grade II (10/12), III (12/20) and IV samples (38/40) (Table 3A). Furthermore, we found that the TRPV1 variants expression levels strongly decreased in TRPV1 positive (TRPV1<sup>+</sup>) glioma samples (grade

III and IV) (Table 3A), except for the TRPV1<sub>v3</sub>, which expression was maintained in grade IV TRPV1<sup>+</sup> samples (Table 3A). In fact, the TRPV1<sub>v3</sub> was found to be the only TRPV1 5'UTR transcript expressed in the majority (n = 38/44) of GBM samples (Table 3A). Moreover, we found that the GBM samples showed different TRPV1<sub>v3</sub> relative expression (Rel. expr.) level, with 50% of GBM samples showing low expression (Rel. expr.  $\leq$  0.5), 36.4 % with high expression (Rel. expr.  $>$  0.5) and 13.6 % with complete loss of TRPV1<sub>v3</sub> expression (Rel. expr. 0) (Table 3B). Evaluation of TRPV1 variant transcripts was also performed in Human Normal Progenitor Cells (HNPCs; n = 3), in Glioma Stem-like Cells (GSCs; n = 4) and in differentiated GSCs (dGSCs; n = 4). As shown (Table 3C), HNPCs sample expressed all the TRPV1 variants, with similar levels found in NHA, two of four GSCs were shown to express TRPV1<sub>v3</sub> only, while after differentiation all the GSCs showed expression of all the TRPV1 variants (Table 3C).

Taken together, these results revealed that TRPV1<sub>v3</sub>, which is the most stable TRPV1 5'UTR variants, is responsible for the TRPV1 expression in GBM and GSCs TRPV1<sup>+</sup> samples, while the complete profile of TRPV1 variants expression was present in NB, NHA and HNPC samples, and with different expression levels in Grade I-III gliomas.

### TRPV1 expression and patient survival

TRPV1 mRNA expression was correlated with patients overall survival (OS). We first calculated the mean and median OS of GBM patients. We found that



**Figure 3: TRPV1 translation regulation by Rap and IFN $\gamma$  in glioma cell lines.** U87 and U251 glioma cell lines were treated with Rap (10  $\mu$ M), or IFN $\gamma$  (100  $\mu$ M) and cellular lysates from treated glioma cells were immunoblotted with anti-TRPV1 antibody. GAPDH was used as loading control. Densitometric analysis was performed by using a ChemiDoc apparatus and software. Data presented are one out of three separate experiments.

**Table 3: TRPV1<sub>v3</sub> expression in GBM samples and GSCs**

A)

TRPV1 5'UTR variants	NB (n=3/3)	NHA (n=2/2)	Grade I (n=8/8)	Grade II (n=10/12)	Grade III (n=12/20)	Grade IV (n=38/44)
TRPV1 <sub>v0</sub>	0.42 ± 0.4	0.22 ± 0.01	0.62 ± 0.22	0.34 ± 0.01	0.16 ± 0.01	0
TRPV1 <sub>v1</sub>	0.61 ± 0.09	0.72 ± 0.11	0.33 ± 0.12	0.26 ± 0.01	0.03 ± 0.01	0
TRPV1 <sub>v3</sub>	0.85 ± 0.12	0.77 ± 0.13	1.12 ± 0.20	0.81 ± 0.19	0.44 ± 0.1	0.43 ± 0.2
TRPV1 <sub>v4</sub>	0.64 ± 0.11	0.61 ± 0.08	0.16 ± 0.01	0.40 ± 0.02	0.22 ± 0.1	0

B)

TRPV1 <sub>v3</sub>	(n= 6/44)	(n= 22/44)	(n=16/44)
Rel. Expr.	0	≤ 0.50	> 0.50
% of samples	13.6	50	36.4

C)

TRPV1 5'UTR variants	HNPC (n=3/3)	GSC (n=2/4)	dGSC (n=4/4)
TRPV1 <sub>v0</sub>	0.42 ± 0.02	0	0.23 ± 0.01
TRPV1 <sub>v1</sub>	0.33 ± 0.02	0	0.27 ± 0.01
TRPV1 <sub>v3</sub>	1.02 ± 0.13	0.25 ± 0.01	0.38 ± 0.02
TRPV1 <sub>v4</sub>	0.22 ± 0.01	0	0.15 ± 0.01

A) TRPV1 5'UTR variants relative expression (Rel. Exp) levels in Normal Brain (NB), Normal Human Astrocytes (NHA) and in glioma biopsies from grade I to IV. B) TRPV1<sub>v3</sub> expression levels in GBM samples, subdivided in three categories: no TRPV1<sub>v3</sub> expression (Rel. Expr. = 0), low TRPV1<sub>v3</sub> (Rel. Expr. ≤ 0.50) and high TRPV1<sub>v3</sub> (Rel. Expr. > 0.50). TRPV1<sub>v3</sub> relative expression levels are indicated. C) TRPV1 5'UTR variants relative expression (Rel. Exp) levels in human normal progenitor cells (HNPC), glioma stem-like cells (GSC) and dGSC (differentiated glioma stem-like cells). n: indicates the number of samples analyzed. A, B) n: indicates the number of TRPV1 positive samples respect to the total samples analyzed. A-C) Data are represented as mean of TRPV1 relative expression ± S.D. of three-separated RT/PCR analysis. Relative values were normalized to GAPDH expression level.

the mean OS was 14.4 months and the median OS was 11.0 months. Then, we evaluated the significance between patients survival (short OS survival < 12 months and long OS survival > 12 months) with the TRPV1<sub>v3</sub> mRNA expression levels of all GBM patients (n = 44) by unpaired *t*-test. TRPV1<sub>v3</sub> mRNA expression reached significance (p = 0.0009) for survival with short OS GBM patients, showing lower TRPV1<sub>v3</sub> mRNA expression compared with long OS patients (Figure 4A). Moreover, on univariate analysis, survival curves were calculated according to the Kaplan–Meier method by evaluating TRPV1<sub>v3</sub> mRNA expression of all patients. TRPV1<sub>v3</sub> mRNA expression reached significance for survival (p = 0.0205) (Figure 4B and Table 4A). Similar results were obtained in a subgroup of GBM patients (n = 6) showing complete loss of TRPV1<sub>v3</sub> mRNA expression, as respect to TRPV1 expressing GBM patients (n = 38) (p = 0.0006) (Figure 4B and Table 4B). Thus, low or absent of TRPV1<sub>v3</sub> expression strongly correlates with short survival in GBM patients.

Additionally we performed a multivariate analysis based on the Cox regression model to test the influence of TRPV1<sub>v3</sub> mRNA expression on the survival of all patients or those with deleted TRPV1<sub>v3</sub> expression. We found that the degree of TRPV1<sub>v3</sub> mRNA expression retained its significance as an independent prognostic factor in all group of patients (P = 0.0008) and in the subgroup with deleted TRPV1<sub>v3</sub> expression (P = 0.0011) (Figure 4C and Table 4B).


## DISCUSSION

Deregulation of gene expression is a hallmark of cancer cells. Acquiring or maintaining a specific profile of expressed proteins may enable the tumor cells to grow, migrate or survive to apoptotic stimuli. Modifications of mRNA stability and/or translation efficiency are increasingly reported in cancers [15, 26]. The UTRs flanking the coding region in mature



mRNA regulate translation or mRNA stability through diverse mechanisms, representing an extra level of gene expression control [26-28]. An increasing number of reports highlight the effect of simple sequence elements or secondary and tertiary structures of the 5' UTR in affecting the translation efficiencies of proto-oncogenes or tumor suppressing genes [15], neurotransmitter

receptors [29] and ion channels [30]. Elements in the 5' UTR can mediate translational regulation via the 5'-cap or the secondary structure, and stable 5' UTR structures can interfere with translation by reducing the accessibility for the translational machinery and ribosomal scanning [31-33]. The TRPV1 channel, whose regulation was investigated in glioma, evidenced different expression



**Figure 4: TRPV1<sub>v3</sub> mRNA expression correlates with survival.** **A.** Distribution of TRPV1<sub>v3</sub> mRNA expression in short survival (OS < 12 months) and long survival (OS > 12 months) GBM patients (n = 44 GBM specimens). Statistical analysis was performed by Unpaired t test at two-tailed (P < 0.05) value. **B.** Kaplan-Meier survival analysis for TRPV1<sub>v3</sub> expressing glioma patients, illustrating an association between: A) survival and TRPV1<sub>v3</sub> mRNA expression based on two categories, high (fold > 2.0) and low (fold < 2.0) TRPV1<sub>v3</sub> levels. **C.** survival and TRPV1<sub>v3</sub> mRNA expression based on two categories, TRPV1<sub>v3</sub> mRNA loss vs expression (n = 44 samples). Associated log-rank test and Cox regression P-values were indicated.

**Table 4: Statistical analysis of TRPV1<sub>v3</sub> in GBM****Table 4A: Univariate Kaplan-Meier survival analysis and TRPV1<sub>v3</sub> mRNA expression (log-rank test)**

	All patients (n = 44) N° events (n = 38)		All patients (n = 44) N° events (n = 44)	
	Log-rank test	P-value	Log-rank test	P-value
TRPV1 <sub>v3</sub> (low/high)	5.367	0.0205		
TRPV1 <sub>v3</sub> (loss/expression)			11.90	0.0006

**Table 4B: Multivariate Cox proportional hazard regression analysis of Kaplan-Meier survival analysis of TRPV1<sub>v3</sub> mRNA expression in relation to survival rates**

	Relative risk (95% CI) All patients (n = 38/44)
TRPV1 <sub>v3</sub> (low/high)	2.25 (1,13-4.45) P = 0,0008
	Relative risk (95% CI) All patients (n = 6/44)
TRPV1 <sub>v3</sub> (loss/expression)	17.1 (3.40-85.10) P = 0.0011

patterns. Our results indicated that among the TRPV1 5'UTR variants, TRPV1<sub>v3</sub> has the most structured and stable 5'UTR sequence, since its secondary 5'UTR structure shows the lowest free energy compared with the other 5'UTR variants. Moreover, experiments using Act D confirmed that TRPV1<sub>v3</sub> in GBM is the most stable TRPV1 5'UTR transcript. Secondary structure and 5'UTR elements can function as major regulatory tool in 5'UTR and are prevalent among mRNAs poorly translated under normal conditions [34]. Our data suggest that TRPV1<sub>v3</sub> is the only representative transcript expressed in TRPV1 positive GBM samples analyzed. Further computational prediction analysis revealed that all TRPV1 5'UTR variants contain a common translational sequence, named TOP, and TOP mRNAs remain sensitive to Rap treatment. In various cell lines, the degree of TOP inhibition by Rap varies, indicating that the effects of Rap are most likely cell type dependent [35-37]. Our results indicated that in GBM cell lines, treated with Rap, the TRPV1 protein levels decrease, suggesting that TRPV1 translation is sensitive to Rap. Since the pro-survival role of autophagy in tumors, including GBM [38], down-regulation of TRPV1 protein by a canonical autophagic inducer is interesting also in the view of a counterattack role of the TRPV1 channel in autophagy, through the induction of apoptosis in GBM cells [22]. Another regulatory element that was evidenced by computational analysis, is the GAIT element, that was found in 5' UTR of TRPV1<sub>v0,v3,v4</sub>. GAIT element has been experimentally demonstrated to be sufficient for mRNA translational silencing, by IFN- $\gamma$ , in human U937 monocytic cells [39]. Our results confirmed that IFN- $\gamma$  is able to reduce TRPV1 protein levels compared with untreated cells, suggesting that GAIT

can be another 5'UTR element able to regulate TRPV1 translation. Altogether, these results evidenced the role of 5'UTR in TRPV1 translation and stability, suggesting novel potential mechanisms to regulate TRPV1 functions in human GBM cell lines. Our and other research data indicate that triggering of TRPV1 by synthetic or endogenous ligands activates apoptotic cell death pathway [22, 23]. Thus, it is conceivable that the reduced or lost expression of TRPV1<sub>v3</sub>, the only TRPV1 variant expressed in GBM, could represent a mechanism by which the GBM cells evade pro-apoptotic signals. Moreover, this hypothesis was supported by the analysis in grade I-III gliomas, where we found that TRPV1 variant expression levels were inversely correlated to the glioma grade. In addition our findings evidenced that, as in TRPV1<sup>+</sup>-GBM samples, GSCs maintain only TRPV1<sub>v3</sub> transcript. Since different mechanisms mediate the resistance of GSCs to cytotoxic therapies and to pro-apoptotic signals [40-42], including down-regulation of TRPV1 [23], this data suggest that reduced TRPV1 expression in GSCs could be associated to their acquired resistance, as in GBM.

Furthermore, herein we showed that by inducing GSCs differentiation the TRPV1<sub>v3</sub> expression increased, and the expression profile of dGSCs was similar to that found in low-grade glioma samples. Accordingly to our data, loss of TRPV1 was associated to proliferation of neural stem cell and neurogenesis reduction [23].

In support of this hypothesis, we found that the reduction of TRPV1<sub>v3</sub> is accompanied by poor prognosis, which is also worsened by the complete loss of TRPV1<sub>v3</sub> mRNA expression. In the same view, TRPV1 mRNA was found to be over-expressed in GBM tissues as respect to NB and TRPV1 expression was significantly higher (5-fold)

in GBM patients with higher OS (more than 12 months) as respect to that showing lower OS (less than 12 months) [25]. No data on the expression of TRPV1 variants in tumors have been provided so far. The only data in cancer is referred to TRPV1 wild type. Thus, in hepatocellular carcinoma, TRPV1 expression correlates with better prognosis of patients [43], while in bladder cancer its reduction represents a prognostic negative biomarker [21].

Overall our results suggest that TRPV1<sub>v3</sub> expression is a potential negative prognostic marker for patients with GBM. In fact, the reduction or null expression of TRPV1<sub>v3</sub> transcript was associated with a short survival of all these patient groups. In a multivariate Cox proportional hazards regression model, TRPV1<sub>v3</sub> expression reached significance as an independent prognostic factor for survival considering all patients and the subgroup characterized by loss of TRPV1<sub>v3</sub> expression.

All together, these data suggested that TRPV1 could have a role in tumor aggressiveness, since loss of reduction of TRPV1 expression is associated with a more proliferative tumor, as also reported for others cancer cell types [20, 22, 43].

In conclusion our results, showing that the TRPV1<sub>v3</sub> has the lowest free energy in its secondary 5'UTR structure and the highest 5'UTR sequence stability, suggest that it may represent a potential prognostic marker for patients with GBM. As an independent prognostic factor for poor disease outcome, TRPV1<sub>v3</sub> may be useful to improve appropriate selection of post-operative follow-up protocol for individual patients. Further studies with a more representative number of GBM samples, are required to completely assess the role of TRPV1 5'UTR identified in GBM patients.

## MATERIALS AND METHODS

### Software for mRNA structure analysis

RegRNA 2.0 was used for identifying functional RNA motifs in 5' UTR TRPV1 RNA sequence [44]. MView reformats the results of a sequence database search (BLAST, FASTA, etc) or a multiple alignment (MSF, PIR, CLUSTAL, etc) and was used for TRPV1 variant transcripts comparative analysis [45]. The structure and the free energy ( $\Delta G$ s) of the TRPV1 variant transcripts were calculated using RNAfold [46].

### Cell cultures and human bioptic samples

U87 and U251 human glioma cell lines were obtained from the American Type Culture Collection (LGC Promochem, Teddington, UK). Glioma cell lines were growth in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mmol/L-glutamine, 100 IU/mL penicillin, 100  $\mu$ g streptomycin at 37°C, 5% CO<sub>2</sub> and 95% of humidity.

Formalin-fixed paraffin-embedded glioma tissues from human tumor biopsies surgically removed from patients who gave informed consent to the study (n = 84), were kindly provided by Prof. Felice Giangaspero (I.N.M., Neuromed, Pozzilli, Isernia, Italy) as previously described [47]. GSC lines previously characterized [42] were cultured in a serum free medium supplemented with 20 ng/ml of epidermal growth factor (EGF) and 10 ng/ml of basic fibroblast growth factor (bFGF). For differentiation, GSC lines were grown for 15 days, in medium supplemented with 5% fetal bovine serum (FBS). HNPC were purchased from Cambrex, (UK) and cultured following manufacturing instruction.

### Compounds

Rap, Act D and IFN- $\gamma$  were purchased from Sigma-Aldrich (Bristol, UK), and aliquots of 25 mM were prepared according to manufacturing instruction.

### RT/PCR analysis

Total RNA (RNAt), from cell lines, was extracted using the RNeasy Mini kit (Qiagen, Milan, IT). RNAt from GBM biopsies was extracted with RNeasy FFPE kit (Qiagen, Milan, IT), as previously described [44]. Total RNA from NHA and NB were purchased (Clontech, USA). Complementary DNA (cDNA) was synthesized from 1  $\mu$ g of RNAt using the high-capacity cDNA archive kit (Life Technology, Milan, IT), in a total volume of 25  $\mu$ l. Real Time Quantitative PCR (qRT-PCR), for TRPV1 variants was performed using specific primers (Supplementary Table 3) and human GAPDH RT<sup>2</sup> qPCR Primer assay (Qiagen) were used to normalize qRT-PCR data. The following thermal cycling conditions: 3' at 95°C; 35 cycles of 10'' at 95°C, 20'' at 60°C, 20'' at 72°C; and finally 50'' at 72°C, using iQ5 Thermal Cycler (Bio-Rad, Hercules, CA). Melting curve was performed to verify primers specificity. One  $\mu$ l of cDNA was used in a final volume of 25  $\mu$ l, with 2X RT<sup>2</sup> SYBR<sup>®</sup> Green qPCR Master mixes (Qiagen) and each sample was amplified in triplicate. Measurement of GAPDH transcript level was used to normalize TRPV1 variants levels. TRPV1 variants levels were calculated by the 2<sup>- $\Delta\Delta C_t$</sup>  method and expressed as relative fold compared with the corresponding control.

### RNA stability assay

Glioma cell lines were treated up to 12 h with Act D (10  $\mu$ g/ml) and RNAt was isolated from the cell pellet using RNeasy mini kit, and eluted in 50  $\mu$ l of H<sub>2</sub>O. The same volume of RNAt samples were run in 1.5% agarose gel electrophoresis, then gel was visualized by UV trans-illuminator and the image of the gel was acquired by Chemi-Doc (BioRad). Real time-PCR with the specific TRPV1 5'UTR variants primers was performed. For each sample, the amount of TRPV1 transcripts was evaluated

relative to 1 µg of RNA<sub>t</sub>, by Real-Time PCR. Briefly, first-strand cDNA was synthesized using 1 µg of RNA<sub>t</sub> and 10 ng of cDNA, for each sample, was amplified with specific TRPV1 variant primers. Experiments were performed in triplicate.

### Western blot analysis

Glioma cell lines were lysed as described previously [44]. Twenty micrograms of the lysates were separated on a SDS polyacrylamide gel, transferred onto Hybond-C extra membranes (GE Healthcare), blocked with 5% low-fat dry milk in PBS-Tween 20, immunoblotted with mouse monoclonal anti-TRPV1 antibody (Ab) (1:1000, Sigma Aldrich), and mouse monoclonal anti-glyceraldehydes-3-phosphate dehydrogenase (GAPDH) Abs overnight and then incubated with HRP-conjugated Ab (1:2000, Cell Signaling) for 1 h. Immunostaining was revealed using an enhanced chemiluminescence Western blotting analysis system (GE Healthcare). Densitometric analyses were performed by ChemiDoc using the Quantity One software (Bio-Rad).

### TOP analysis

Glioma cell lines were treated for 24 h with Rap (10 µM), then cell pellets were lysed for western blot analysis.

### GAIT analysis

GAIT regulation of TRPV1 variants translation was determined, by treating glioma cell lines with IFN-γ (100 µM) for 24 h. Western blot analysis were performed to evaluate TRPV1 protein levels.

### Statistical analysis

The statistical significance of Ct variation levels was determined by Student's *t*-test. Statistical analysis was performed using the Kruskal–Wallis test for comparison of TRPV1 mRNA expression groups. *P*-value ≤0.05 was considered significant. Patient follow-up was evaluated as the number of months from the date of the diagnostic surgical procedure to that of last visit or death. Survival time was defined as the period between the time of diagnosis and the time of death.

Statistical analysis was performed using GraphPad Prism 9.0 software (GraphPad software, San Diego, CA, USA). Univariate survival analysis was performed according to the Kaplan–Meier method, and differences in the survival curves were assessed with the log-rank test. Multivariate survival analysis was performed using Cox's proportional regression analysis and the relative risk was calculated with 95% confidence interval (CI). A *P*-value ≤0.05 was considered statistically significant.

## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## GRANT SUPPORT

This study was supported by AIRC IG 2014, cod. 15821, FAR UNICAM.

## REFERENCES

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature*. 1997; 389: 816-824.
2. Nabissi M, Santoni G. TRPV1 (transient receptor potential cation channel, subfamily V, member 1). *Atlas Genet Cytogenet Oncol Haematol*. 2011; 15: 588-595.
3. Vázquez E, Valverde MA. A review of TRP channels splicing. *Semin Cell Dev Biol*. 2006;17:607-617.
4. Schumacher MA, Eilers H. TRPV1 splice variants: structure and function. *Front Biosci (Landmark Ed)*. 2010; 15: 872-882.
5. Lu G, Henderson D, Liu L, Reinhart PH, Simon SA. TRPV1b, a functional human vanilloid receptor splice variant. *Mol Pharmacol*. 2005; 67: 1119-1127.
6. Tian W, Fu Y, Wang DH, Cohen DM. Regulation of TRPV1 by a novel renally expressed rat TRPV1 splice variant. *Am J Physiol Renal Physiol*. 2006; 290: F117–126.
7. Gebauer F, Hentze MW. Molecular mechanisms of translational control. *Nat Rev Mol Cell Biol*. 2004; 5: 827-835.
8. Pichon X, Wilson LA, Stoneley M, Bastide A, King HA, Somers J, Willis AE. RNA binding protein/RNA element interactions and the control of translation. *Curr Protein Pept Sci*. 2012; 13: 294-304.
9. Paek KY, Hong KY, Ryu I, Park SM, Keum SJ, Kwon OS, Jang SK. Translation initiation mediated by RNA looping. *Proc Natl Acad Sci U S A*. 2015; 112: 1041-1046.
10. Bugaut A, Balasubramanian S. 5'-UTR RNA G-quadruplexes: translation regulation and targeting. *Nucleic Acids Res*. 2012; 40: 4727-4741.
11. Levy S, Avni D, Hariharan N, Perry RP, Meyuhos O. Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control. *Proc Natl Acad Sci U S A*. 1991; 88: 3319-3323.
12. Kapasi P, Chaudhuri S, Vyas K, Baus D, Komar AA, Fox PL, Merrick WC, Mazumder B. L13a blocks 48S assembly: role of a general initiation factor in mRNA-specific translational control. *Mol Cell*. 2007; 25: 113-126.
13. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. *J Cell Biol*. 1991; 115: 887-903.

14. Turner JD, Vernocchi S, Schmitz S, Muller CP. Role of the 5'-untranslated regions in post-transcriptional regulation of the human glucocorticoid receptor. *Biochim Biophys Acta*. 2014; 1839: 1051-1061.
15. Audic Y, Hartley RS. Post-transcriptional regulation in cancer. *Biol Cell*. 2004; 96: 479-498.
16. Sanchez MG, Sanchez AM, Collado B, Malagarie-Cazenave S, Olea N, Carmena MJ, Prieto JC, Diaz-Laviada II. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. *Eur J Pharmacol*. 2005; 515: 20-27.
17. Dömötör A, Peidl Z, Vincze A, Hunyady B, Szolcsányi J, Kereskay L, Szekeres G, Mózsik G. Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. *Inflammopharmacology*. 2005; 13: 161-177.
18. Hartel M, di Mola FF, Selvaggi F, Mascetta G, Wente MN, Felix K, Giese NA, Hinz U, Di Sebastiano P, Büchler MW, Friess H. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. *Gut*. 2006; 55: 519-528.
19. Wu TT, Peters AA, Tan PT, Roberts-Thomson SJ, Monteith GR. Consequences of activating the calcium-permeable ion channel TRPV1 in breast cancer cells with regulated TRPV1 expression. *Cell Calcium*. 2014; 56: 59-67.
20. Amantini C, Ballarini P, Caprodossi S, Nabissi M, Morelli MB, Lucciarini R, Cardarelli MA, Mammana G, Santoni G. Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. *Carcinogenesis*. 2009; 30: 1320-1329.
21. Kalogris C, Caprodossi S, Amantini C, Lambertucci F, Nabissi M, Morelli MB, Farfariello V, Filosa A, Emiliozzi MC, Mammana G, Santoni G. Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters. *Histopathology*. 2010; 57: 744-752.
22. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, Giangaspero F, Santoni G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. *J Neurochem*. 2007; 102: 977-990.
23. Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith ES, Wend P, Purfürst B, Nuber UA, Gurok U, Matyash V, Wälzlein JH, Chirasani SR. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. *Nat Med*. 2012; 18: 1232-1238.
24. Schonberg DL, Bao S, Rich JN. TRP-ing up brain tumors. *Nat Med*. 2012; 18: 1175-1176.
25. Alptekin M, Eroglu S, Tutar E, Sencan S, Geyik MA, Ulasli M, Demiryurek AT, Camci C. Gene expressions of TRP channels in glioblastoma multiforme and relation with survival. *Tumour Biol*. 2015; 36: 9209-9213.
26. Diederich S, Bartsch L, Berkmann JC, Fröse K, Heitmann J, Hoppe C, Iggena D, Jazmati D, Karschnia P, Linsenmeier M, Maulhardt T, Möhrmann L, Morstein J, et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. *EMBO Mol Med*. 2016; 8: 442-457.
27. Di Liegro CM, Schiera G, Di Liegro I. Regulation of mRNA transport, localization and translation in the nervous system of mammals. *Int J Mol Med*. 2014; 33: 747-762.
28. Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5'-untranslated regions of eukaryotic mRNAs. *Science*. 2016; 352: 1413-1416.
29. Eggert M, Aichinger E, Pfaffl MW, Steinlein OK, Pfohl M. Nicotinic acetylcholine receptor subunits  $\alpha 4$  and  $\alpha 5$  associated with smoking behaviour and lung cancer are regulated by upstream open reading frames. *PLoS One*. 2013; 8: e66157.
30. Gan L, Hahn SJ, Kaczmarek K. Cell type-specific expression of the Kv3.1 gene is mediated by a negative element in the 5' Untranslated region of the Kv3.1 promoter. *J Neurochemistry*. 1999; 73: 1350-1362.
31. Signori E, Bagni C, Papa S, Primerano B, Rinaldi M, Amaldi F, Fazio VM. A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes downmodulation of translation efficiency. *Oncogene*. 2001; 20: 4596-4600.
32. Wang J, Lu C, Min D, Wang Z, Ma X. A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. *J Int Med Res*. 2007; 35: 564-573.
33. Kutchko KM, Sanders W, Ziehr B, Phillips G, Solem A, Halvorsen M, Weeks KM, Moorman N, Laederach A. Multiple conformations are a conserved and regulatory feature of the RB1 5' UTR. *RNA*. 2015; 21: 1274-1285.
34. Davuluri RV, Suzuki Y, Sugano S, Zhang MQ. CART classification of human 5' UTR sequences. *Genome Res*. 2002; 10: 1807-1816.
35. Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. *Mol Cell Biol*. 2001; 21: 8671-8683.
36. Saito K, Chen M, Bard F, Chen S, Zhou H, Woodley D, Polischuk R, Schekman R, Malhotra V. TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites. *J Mol Biol*. 2004; 344: 383-394.
37. de Turris V, Di Leva G, Caldarola S, Loreni F, Amaldi F, Bozzoni I. TOP promoter elements control the relative ratio of intron-encoded snoRNA versus spliced mRNA biosynthesis. *Neurosci. Lett*. 2014; 578: 211-216.

38. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, et al. Autophagy in malignant transformation and cancer progression. *EMBO J*. 2015; 34: 856-880.
39. Sampath P, Mazumder B, Seshadri V, Fox PL. Transcript-selective translational silencing by gamma interferon is directed by a novel structural element in the ceruloplasmin mRNA 3' untranslated region. *Mol Cell Biol*. 2003; 23: 1509-1519.
40. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature*. 2006; 444:756-760.
41. Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, Zhang Z, Li C, Li Y. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. *Oncotarget*. 2015; 6:32930-32943. doi: 10.18632/oncotarget.5405.
42. Morelli MB, Nabissi M, Amantini C, Farfariello V, Ricci-Vitiani L, di Martino S, Pallini R, Larocca LM, Caprodossi S, Santoni M, De Maria R, Santoni G. The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. *Int J Cancer*. 2012;131:E1067-1077.
43. Miao X, Liu G, Xu X, Xie C, Sun F, Yang Y, Zhang T, Hua S, Fan W, Li Q, Huang S, Wang Q, Liu G, et al. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet*. 2008; 186: 25-32.
44. Chang TH, Huang HY, Hu JB, Weng SL, Horng JT, Huang HD. An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. *BMC Bioinformatics*. 2013; 14 Suppl 2: S4.
45. Squizzato S, Park YM, Buso N, Gur T, Cowley A, Li W, Uludag M, Pundir S, Cham JA, McWilliam H, Lopez R. The EBI Search engine: providing search and retrieval functionality for biological data from EMBL-EBI. *Nucleic Acids Res*. 2015; 43: W585-588.
46. Lorenz R, Bernhart SH, Höner Zu Siederdisen C, Tafer H, Flamm C, Stadler PF, Hofacker IL. ViennaRNA Package 2.0. *Algorithms Mol Biol*. 2011; 6: 26.
47. Nabissi M, Morelli MB, Amantini C, Farfariello V, Ricci-Vitiani L, Caprodossi S, Arcella A, Santoni M, Giangaspero F, De Maria R, Santoni G. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. *Carcinogenesis*. 2010; 31: 794-803.